KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest & Investment Income: 2009-2025

Historic Interest & Investment Income for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Sep 2025 value amounting to $28.7 million.

  • Alnylam Pharmaceuticals' Interest & Investment Income fell 10.78% to $28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.9 million, marking a year-over-year decrease of 4.55%. This contributed to the annual value of $122.0 million for FY2024, which is 27.66% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Interest & Investment Income of $28.7 million as of Q3 2025, which was up 4.35% from $27.5 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Interest & Investment Income registered a high of $32.1 million during Q3 2024, and its lowest value of $225,000 during Q3 2021.
  • For the 3-year period, Alnylam Pharmaceuticals' Interest & Investment Income averaged around $27.5 million, with its median value being $28.7 million (2025).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Interest & Investment Income plummeted by 91.79% in 2021 and then spiked by 3,375.56% in 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $495,000 in 2021, then spiked by 2,743.84% to $14.1 million in 2022, then soared by 116.00% to $30.4 million in 2023, then climbed by 2.02% to $31.0 million in 2024, then decreased by 10.78% to $28.7 million in 2025.
  • Its Interest & Investment Income stands at $28.7 million for Q3 2025, versus $27.5 million for Q2 2025 and $28.7 million for Q1 2025.